Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Common Equity (2016 - 2025)

Historic Common Equity for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $776.7 million.

  • Amphastar Pharmaceuticals' Common Equity rose 674.31% to $776.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $776.7 million, marking a year-over-year increase of 674.31%. This contributed to the annual value of $732.3 million for FY2024, which is 1452.52% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Common Equity of $776.7 million as of Q3 2025, which was up 674.31% from $757.5 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Common Equity high stood at $776.7 million for Q3 2025, and its period low was $430.2 million during Q3 2021.
  • Its 5-year average for Common Equity is $595.3 million, with a median of $589.2 million in 2023.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Common Equity crashed by 460.93% in 2021 and then skyrocketed by 2256.37% in 2024.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Common Equity stood at $445.5 million in 2021, then rose by 18.66% to $528.7 million in 2022, then rose by 20.95% to $639.4 million in 2023, then grew by 14.53% to $732.3 million in 2024, then rose by 6.07% to $776.7 million in 2025.
  • Its Common Equity was $776.7 million in Q3 2025, compared to $757.5 million in Q2 2025 and $751.3 million in Q1 2025.